EuBiologics Balance Sheet Health
Financial Health criteria checks 3/6
EuBiologics has a total shareholder equity of ₩104.8B and total debt of ₩12.3B, which brings its debt-to-equity ratio to 11.7%. Its total assets and total liabilities are ₩151.8B and ₩47.0B respectively. EuBiologics's EBIT is ₩7.7B making its interest coverage ratio 23.8. It has cash and short-term investments of ₩11.5B.
Key information
11.7%
Debt to equity ratio
₩12.26b
Debt
| Interest coverage ratio | 23.8x |
| Cash | ₩11.49b |
| Equity | ₩104.82b |
| Total liabilities | ₩46.99b |
| Total assets | ₩151.81b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A206650's short term assets (₩41.8B) exceed its short term liabilities (₩25.7B).
Long Term Liabilities: A206650's short term assets (₩41.8B) exceed its long term liabilities (₩21.3B).
Debt to Equity History and Analysis
Debt Level: A206650's net debt to equity ratio (0.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if A206650's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if A206650 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if A206650 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.